Pfizer’s smoking cessation drug Chantix carries too many risks and should only be tried when other treatments fail, researchers said. Chantix was eight times more likely to be linked with a reported case of suicidal behavior or depression than other nicotine replacement products, such as the nicotine patch, they said. The findings contradict two studies released last month by...
